147 results about "Optic vesicle" patented technology

Compositions and methods for administering collagen to a human subject have been developed. The collagen-containing lipid vesicles of the invention provide a delivery system for human collagen which eliminates problems associated with chemical and physical instability of the collagen as well as immune responses to non-human collagen.

Novel ultrasound methods comprising administering to a patient a targeted vesicle composition which comprises vesicles comprising a lipid, protein or polymer, encapsulating a gas, in combination with a targeting ligand, and scanning the patient using ultrasound. The scanning may comprise exposing the patient to a first type of ultrasound energy and then interrogating the patient using a second type of ultrasound energy. The targeting ligand preferably targets tissues, cells or receptors, including myocardial cells, endothelial cells, epithelial cells, tumor cells and the glycoprotein GPIIbIIIa receptor. The methods may be used to detect a thrombus, enhancement of an old or echogenic thrombus, low concentrations of vesicles and vesicles targeted to tissues, cells or receptors.

Novel lipid compounds are provided that may be termed "pro-cationic" in that they are neutral or negatively charged until they are either brought into contact with cellular membranes or are internalized by cells. The lipids have a hydrophobic tail group and a hydrophilic head group, the head group incorporating both a positively and negatively charged region at physiological pH. The hydrophobic tail group is stably connected to the positive region of the head group which in turn is connected to the negative region by a disulfide bond that is susceptible to cleavage by membrane-bound and intracellular factors. Cleavage of the disulfide bond removes the negatively charged region from the head group resulting in a lipid that is cationic and therefor fusogenic with negatively charged cell membranes. Consequently, lipids of the invention are useful as components of liposomes that serve as vehicles for delivering pharmaceutical agents into cells with reduced toxicity.

Vesicles for delivery of active macromolecules which are formed from amphiphilic segmented copolymers having one or more mucoadhesive groups or regions and which can be used for delivery of an active agent to an area of the body having a mucous membrane, such as but not limited to the gastrointestinal tract.

The present invention generally relates to compositions and methods for topical or transdermal delivery and treatment of wounds and/or promoting wound healing. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., wounded skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

The present invention provides a composite material, preferably an ophthalmic device, more preferably a contact lens, which comprises a vesicle-containing coating including at least one layer of a vesicle and one layer of a polyionic material having charges opposite the charges of the vesicle. Such composite material can find use in biomedical applications, for example, a device for localized drug delivery and an in vivo analyte sensor such as glucose sensing contact lens. By lifting off the vesicle-containing coating from a substrate, a self-standing membrane (film) capable of encapsulating a wide variety of guest materials can be prepared. In addition, the invention provides methods for making vesicle-containing composite and film materials of the present invention.

An amphiphilic compound is provided capable of forming vesicles or liposomes, said amphiphilic compound having at least one headgroup containing a selectively cleavable group or moiety such as a residue of a choline or phenylalanine derivative, and at least one hydrogen-bonding group located either within said headgroup and/or in close proximity thereto. The cleavable group or moiety is cleaved under selective conditions including change of chemical, physical or biological environment and is preferably cleaved enzymatically in a biological environment such as the brain or the blood. Vesicles or liposomes made from said amphiphilic compounds are suitable for delivery of a therapeutic substance or a diagnostic agent specifically to a target organ or tissue, or for delivery of a nucleic acid for gene therapy.

Methods for treating and preventing middle ear infections by transmembrane administration of medicament-containing transmembrane carrier compositions, such as liposomes and other lipid vesicles, to the tympanic membrane. Medicaments useful for treating pain, inflammation or infection in the outer ear may be co-administered. If utilized for transmembrane administration, the liposomes or other lipid vesicles will usually not be sterically stabilized. The medicaments delivered according to the methods of the invention include antibiotic, anti-viral, anti-fungal and anti-inflammatory agents that are useful in treatment and/or prophylaxis of middle ear infections and their sequelae.

The invention pertains to the field of pharmaceutical technology, which more particularly relates to an elastic nano-vesicle carrier which can transport the active ingredients of the drug to penetrate the natural permeability barrier or pores (such as skin, mucosa, and organs, etc.) and the preparation method, as well as the usage. The vesicle has lipid double molecular layers for transporting one or more active ingredients to penetrate the natural barrier. The vesicle at least contains three dressing components of phospholipid, membrane softener and alcohol, and the three have different physical and chemical properties. The diameter of the typical nano-vesicle is less than 200nm. The vesicle carrier containing the active ingredients of the drug can be applied in the injection, spray and the transdermal preparation.

The present invention provides compositions of yeast extracellular vesicles comprising biologically active molecules, methods for making the same, and methods for the use of the yeast extracellular vesicles to deliver biologically active molecules to target cells. In addition, the invention provides cells and compositions comprising the biologically active molecules and vesicles, which can be used as transfection reagents. The invention further provides methods for producing said compositions of biologically active molecules with vesicles as well as the cells that produce those compositions. Compositions and methods for delivering biologically active molecules, such as a small molecule, a DNA expression plasmid, an RNA molecule, a peptide, or a protein, to cells and/or tissues are provided. The compositions and cells are useful, for example, in delivering biologically active RNA molecules to cells to modulate target gene expression in the diagnosis, prevention, amelioration, and/or treatment of diseases, disorders, or conditions in a subject or organism.

Aspects of the invention provide hollow nanoparticles and uses thereof. In particular, the invention provides membrane-enclosed vesicles comprising a truncated form of an HBsAg S protein lacking one or two of its amino-terminal transmembrane domains.

The invention discloses arginine hybrid cell-penetrating peptide and application thereof, belonging to the field of biological molecule. The cell-penetrating peptide is prepared by hybrid construction from non-natural D-arginine (r) and natural L-arginine (R) and has a structure of (r) n (R) m, wherein r and R can be randomly arranged in the structure, n and m are the number of amino acid residues, the sum of n and m is greater than or equal to 4 and less than or equal to 12, n is greater than or equal to 1 and less than or equal to 11, and m is greater than or equal to 1 and less than or equal to 11; and the N end and the C end of the cell-penetrating peptide can be singly or simultaneously connected with different markers or cargo molecules and carry the markers and the cargo molecules into cells. The cell-penetrating peptide can carry the markers and the cargo molecules into the cells with high efficiency and low cytotoxicity, simultaneously has very strong enzymolysis resistant and serum degradation resistant capacities, and can escape from vesicles corpuscles after entering the cells.

The invention provides a cross-linked biologically degradable carrier polymer, a micelle and a vesicle, and a preparation method and an application of the cross-linked biologically degradable carrier polymer, micelle and vesicle, belonging to the field of biological medical material and solving a poor stability problem of the existing polymer micelle and vesicle. The carrier polymer is an A-B-C tri-block polymer, wherein the block A is polyethylene glycol, the block B is the polyethylene glycol containing functional groups in a lateral chain, and the block C is biologically degradable polyester. The invention also provides the polymer micelle and vesicle, which is formed by self assembly of the carrier polymer, wherein the size of the polymer micelle is 20-1000nm, and the size distribution is 0.01-0.50; the size of the vesicle is 20-1000nm, and the size distribution is 0.01-0.50. The polymer micelle provided by the invention can package fat-soluble matters; and the polymer vesicle canpackage water-soluble matters and the fat-soluble matters at the same time; and the polymer micelle or the vesicle has better mechanical strength and stability because the polymer micelle or the vesicle contains a transitional layer formed by the cross-linked block B.

The invention pertains to the technical field of porous material, in particular to a dioxide vesicle material with a controllable shape, a controllable size and a controllable wall thickness and a preparation method thereof. The invention adopts a sol-gel method to synthetize novel silicon dioxide vesicle material with the controllable shape, an adjustable aperture and an alterable wall thickness in a near-neutral aqueous solution system. The preparation method comprises the steps such as collaborative self-assembly, hydrothermal treatment, drying, roasting to remove a template agent, etc. of the sol-gel process of vesicle with various patterns. The reaction conditions of the invention are mild, the operation is simple and easy and the material structure is rich and controllable. The shape, the size, the wall thickness, etc. of the material can be effectively adjusted and controlled by changing the conditions of the ratio of silicon sources and a surface active agent and the mol ratio of different silicon sources and by adjusting the mass ratio of composing different polymers, etc. The vesicle material has wide applicable prospect in the fields of adsorption, catalyst carriers, slow release of drug, separation, chromatogram, paints, micro reactors, etc.

Engineered exosomes for the delivery of bioactive cargo are provided. The exosomes incorporate a tetraspanin transmembrane anchoring scaffold onto the membrane of the exosome. The tetraspanin transmembrane anchoring scaffold has a C-terminal attachment site in the inner-vesicle space of the exosome, a N-terminal attachment site in the inner-vesicle space or the outer-vesicle space, and/or a loop attachment site in the outer-vesicle space. Peptides can be attached to the different attachments sites in any form or combination. Tetrapanins naturally anchor on the exosome membrane, are biocompatible, and allow for robust loading and delivery of bioactive cargos in mammalian system.

The invention relates to the technical field of biological separation and extraction, in particular to an extracting method of extracellular vesicles. The method comprises the steps that a biologicalsample is provided; the biological sample is in contact with a capturing surface at least twice on the condition that impurities in the biological sample are partially or wholly reserved on the capturing surface, wherein the impurities are partial or whole other substances except the extracellular vesicles in the biological sample, and the capturing surface comprises an inner surface and/or outersurface of a spherical-particle porous material; when the impurities are partially or wholly reserved on the surface of a capture, breakthrough liquid is extracted liquid containing the extracellularvesicles; or the breakthrough liquid is further concentrated. By means of the method, the epicyte vesicles can be quickly separated and purified, the separation operation is simple, the single use cost is low, the separated sample in high in purity, the bioactivity of the sample is kept good, and the extracting method is applied to fundamental research in the aspects of biomarker discovery, biotherapy and the like and industrial production.